Vertex Pharmaceuticals market cap is $47.3 b, and annual revenue was $6.21 b in FY 2020

Vertex Pharmaceuticals Gross profit (Q1, 2021)1.5 B

Vertex Pharmaceuticals Gross profit margin (Q1, 2021), %88.8%

Vertex Pharmaceuticals Net income (Q1, 2021)653.1 M

Vertex Pharmaceuticals EBIT (Q1, 2021)887.8 M

Vertex Pharmaceuticals Cash, 31-Mar-20216.3 B

Vertex Pharmaceuticals EV41.9 B

Vertex Pharmaceuticals revenue was $6.21 b in FY, 2020 which is a 49.1% year over year increase from the previous period.

Vertex Pharmaceuticals revenue breakdown by business segment: 12.9% from KALYDECO, 14.6% from ORKAMBI, 10.1% from SYMDEKO/SYMKEVI and 62.3% from TRIKAFTA/KAFTRIO

USD | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|

## Revenue | 3.0b | 4.2b | 6.2b |

| 37% | 49% | |

## Cost of goods sold | 409.5m | 547.8m | 736.3m |

## Gross profit | 2.6b | 3.6b | 5.5b |

| 87% | 87% | 88% |

## R&D expense | 1.4b | 1.8b | 1.8b |

## General and administrative expense | 557.6m | 658.5m | 770.5m |

## Operating expense total | 2.0b | 2.4b | 2.6b |

## EBIT | 635.2m | 1.2b | 2.9b |

| 21% | 29% | 46% |

## Interest expense | 58.5m | 58.2m | |

## Interest income | 63.7m | 22.2m | |

## Pre tax profit | 600.2m | 1.4b | 3.1b |

## Income tax expense | (1.5b) | 218.1m | 405.2m |

## Net Income | 2.1b | 1.2b | 2.7b |

## EPS | 8.1 | 4.5 | 10.3 |

USD | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
---|---|---|---|---|---|---|---|

## Revenue | 858.4m | 941.3m | 949.8m | 1.5b | 1.5b | 1.5b | 1.7b |

## Cost of goods sold | 95.1m | 135.7m | 131.9m | 162.5m | 184.5m | 186.2m | 192.3m |

## Gross profit | 763.3m | 805.6m | 817.9m | 1.4b | 1.3b | 1.4b | 1.5b |

| 89% | 86% | 86% | 89% | 88% | 88% | 89% |

## R&D expense | 339.5m | 379.1m | 555.9m | 448.5m | 420.9m | 493.5m | 456.0m |

## General and administrative expense | 147.0m | 156.5m | 159.7m | 182.3m | 191.8m | 184.6m | 192.1m |

## Operating expense total | 486.5m | 535.6m | 718.6m | 632.4m | 621.9m | 679.8m | 644.2m |

## EBIT | 276.8m | 270.0m | 99.3m | 720.2m | 718.0m | 672.2m | 887.8m |

| 32% | 29% | 10% | 48% | 47% | 44% | 51% |

## Interest expense | 14.9m | 14.8m | 14.5m | 14.1m | 13.9m | 13.9m | 15.7m |

## Interest income | 15.6m | 18.1m | 17.6m | 12.6m | 4.2m | 3.1m | 1.5m |

## Pre tax profit | 320.2m | 327.1m | 70.7m | 657.5m | 824.8m | 745.9m | 821.0m |

## Income tax expense | 51.5m | 59.7m | 13.1m | 54.8m | (12.5m) | 78.4m | 167.8m |

## Net Income | 268.6m | 267.4m | 57.5m | 602.8m | 837.3m | 667.4m | 653.1m |

## EPS | 1.0 | 1.0 | 0.2 | 2.3 | 3.2 | 2.5 | 2.5 |

USD | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|

## Cash | 2.7b | 3.1b | 6.0b |

## Accounts Receivable | 409.7m | 633.5m | 885.4m |

## Prepaid Expenses | 140.8m | 213.5m | 308.4m |

## Inventories | 124.4m | 167.5m | 280.8m |

## Current Assets | 3.8b | 4.8b | 8.1b |

## PP&E | 812.0m | 745.1m | 958.5m |

## Goodwill | 50.4m | 1.0b | 1.0b |

## Total Assets | 6.2b | 8.3b | 11.8b |

## Accounts Payable | 111.0m | 87.6m | 155.1m |

## Short-term debt | 9.8m | ||

## Current Liabilities | 1.1b | 1.3b | 1.9b |

## Long-term debt | 581.6m | 538.6m | 889.5m |

## Total Debt | 591.4m | 538.6m | 889.5m |

## Total Liabilities | 1.8b | 2.2b | 3.1b |

## Common Stock | 2.5m | 2.6m | 2.6m |

## Additional Paid-in Capital | 7.4b | 7.9b | 7.9b |

## Retained Earnings | (3.0b) | (1.9b) | 858.7m |

## Total Equity | 4.4b | 6.1b | 8.7b |

## Debt to Equity Ratio | 0.1 x | 0.1 x | 0.1 x |

## Debt to Assets Ratio | 0.1 x | 0.1 x | 0.1 x |

## Financial Leverage | 1.4 x | 1.4 x | 1.4 x |

USD | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|

## Net Income | 2.1b | 1.2b | 2.7b |

## Depreciation and Amortization | 72.4m | 106.9m | 109.5m |

## Accounts Receivable | (108.2m) | (225.6m) | (223.4m) |

## Inventories | (32.0m) | (64.0m) | (132.0m) |

## Accounts Payable | 36.6m | (22.8m) | 51.3m |

## Cash From Operating Activities | 1.3b | 1.6b | 3.3b |

## Purchases of PP&E | (95.5m) | (75.5m) | (259.8m) |

## Cash From Investing Activities | (202.2m) | (1.2b) | 99.4m |

## Long-term Borrowings | (33.4m) | (39.2m) | (42.3m) |

## Cash From Financing Activities | (71.2m) | 126.8m | (505.3m) |

## Net Change in Cash | 990.7m | 462.4m | 2.9b |

## Interest Paid | 66.5m | 55.6m | 54.5m |

## Income Taxes Paid | 12.4m | 24.7m | 191.8m |

USD | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
---|---|---|---|---|---|---|---|

## Net Income | 268.6m | 536.1m | 593.6m | 602.8m | 1.4b | 2.1b | 653.1m |

## Depreciation and Amortization | 27.1m | 54.8m | 80.7m | 26.8m | 53.5m | 80.2m | 28.8m |

## Accounts Receivable | (30.1m) | (55.9m) | (41.4m) | (223.7m) | (164.1m) | (151.2m) | (98.4m) |

## Inventories | (13.1m) | (25.2m) | (45.3m) | (27.4m) | (64.4m) | (94.9m) | (22.8m) |

## Accounts Payable | (24.1m) | (28.1m) | (12.2m) | 14.3m | 14.7m | 16.2m | (10.6m) |

## Cash From Operating Activities | 324.8m | 788.5m | 1.1b | 815.7m | 1.9b | 2.8b | 921.1m |

## Purchases of PP&E | (18.0m) | (34.4m) | (58.7m) | (19.4m) | (37.3m) | (212.1m) | (70.9m) |

## Cash From Investing Activities | (39.1m) | (89.3m) | (338.3m) | 31.7m | 103.6m | (144.4m) | (74.3m) |

## Long-term Borrowings | (9.4m) | (18.9m) | (28.9m) | (10.3m) | (20.7m) | (31.4m) | (12.2m) |

## Cash From Financing Activities | (42.0m) | (55.0m) | (34.6m) | (359.4m) | (239.4m) | (380.1m) | (518.7m) |

## Net Change in Cash | 243.3m | 643.4m | 746.3m | 481.3m | 1.7b | 2.2b | 324.1m |

## Interest Paid | 13.1m | 27.1m | 41.7m | 13.8m | 27.3m | 40.8m | 14.5m |

## Income Taxes Paid | 1.8m | 10.9m | 22.8m | 5.8m | 36.8m | 81.7m | 10.7m |

USD | FY, 2018 |
---|---|

## EV/EBIT | 63.4 x |

## EV/CFO | 31.7 x |

## Revenue/Employee | 1.2m |

## Debt/Equity | 0.1 x |

## Debt/Assets | 0.1 x |

## Financial Leverage | 1.4 x |

## P/E Ratio | 20.5 |

FY, 2020 | |
---|---|

Male (Board), percent | 20% |

Female (Board), percent | 13.3% |

Male (Senior Leadership), percent | 20.7% |

Female (Senior Leadership), percent | 12.7% |

Male, percent | 15.7% |

Female, percent | 17.7% |

- Source: www.vrtx.com